Previous 10 | Next 10 |
home / stock / nvs / nvs articles
As President Joe Biden prepares for his State of the Union address on Thursday, he's expected to touch on several key issues including Bidenom...
Monday, Novartis AG (NYSE:NVS) presented new data for Zolgensma (onasemnogene abeparvovec), a one-time gene therapy for the tre...
Monday, Roche Holdings AG (OTC:RHHBY) announced data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal ...
JP Morgan assumed coverage on BeiGene Ltd (NASDAQ:BGNE), highlighting the potential upside and emphasizing that the recent pullback ...
Monday, Novartis AG (NYSE:NVS) made a voluntary public takeover offer to acquire MorphoSys AG (NASDAQ:MOR) for ?...
MorphoSys AG (NASDAQ:MOR) shares are trading higher Monday following a report suggesting Novartis AG (NYSE:NVS) is in talks to acquire the company....
Under the Inflation Reduction Act, Medicare is poised to send initial offers to manufacturers of the first ten drugs chosen for negotiation, challe...
Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter ...
Wednesday, Novartis AG (NYSE:NVS) reported fourth-quarter 2023 net sales of $11.42 billion, up 8% (up 10% at constant currency,...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...